<DOC>
	<DOCNO>NCT01363037</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics combination dapivirine maraviroc vaginal ring determine whether safe use continuously 28 day healthy woman United States .</brief_summary>
	<brief_title>Safety Pharmacokinetics Dapivirine/Maraviroc Vaginal Ring</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Age 18 40 year ( inclusive ) screening , verify per site SOPs Able willing provide write informed consent screen take part study Able willing provide adequate locator information , define site SOPs HIVuninfected , base testing perform study staff Screening Enrollment ( per applicable algorithm Appendix II ) In general good health Screening Enrollment , determine site IoR designee At Screening , participant state willingness abstain receptive sexual activity ( include oral , vaginal anal intercourse ) 14 day prior enrollment duration study participation Per participant report , use effective method contraception Enrollment , intend continue use effective method duration study participation . Effective method include hormonal method ( except contraceptive vaginal ring ) , intrauterine device ( IUD ) insert least 28 day prior enrollment , woman identifies woman sex woman exclusively , sterilization , and/or sexually abstinent past 90 day Satisfactory Pap result 12 calendar month prior Enrollment consistent Grade 0 accord Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) , satisfactory evaluation treatment require Grade 1 high Pap result per American Society Colposcopy Cervical Pathology ( ASCCP ) guideline 12 calendar month prior Enrollment . Per participant report Screening Enrollment , agree participate research study involve drug , medical device , vaginal product duration study participation Per participant report Screening , regular menstrual cycle least 21 day menses ( apply participant report use progestinonly method contraception screening , e.g. , DepoProvera levonorgestrelreleasing IUD ) At Screening Enrollment , participant state willingness refrain insert nonstudy vaginal product object vagina , include limited , spermicide , female condom , diaphragm , contraceptive vaginal ring , vaginal medication , menstrual cup , cervical cap ( vaginal barrier method ) , douche , lubricant , sex toy ( vibrator , dildo , etc . ) , tampon 5 day prior enrollment throughout duration study participation . Note : At Screening visit participant also agree refrain practice list least 5 day prior enrollment . Participant report follow Screening : Known adverse reaction silicone , titanium dioxide , component study product Use and/or anticipate use period study participation CYP3A inducer ( ) and/or inhibitor ( ) Chronic and/or recurrent candidiasis Nontherapeutic injection drug use 12 month prior screen Postexposure prophylaxis HIV exposure within 6 month prior screen Last pregnancy outcome 90 day less prior screen Currently breastfeed Hysterectomy Intends become pregnant within next 4 month Has plan relocate away study site area next 4 month Reports participate research study involve drug , medical device , vaginal product 60 day less prior enrollment At Screening Enrollment , determine IoR/designee , significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease , increase risk cardiovascular event Has follow laboratory abnormality Screening : Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) Grade 1 high per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) Calculated creatinine clearance le 60 mL/min Cockcroft Gault formula , creatinine clearance ( female ) mL/min = ( 140 age year ) x ( weight kg ) x ( 0.85 ) /72 x ( creatinine mg/dL ) Hemoglobin Grade 1 high per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) Platelet count Grade 1 high per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) Note : Otherwise eligible participant exclusionary test result may retested screen process . If participant test nonexclusionary result document within 45 day provide informed consent screening , participant may enrol . At Screening Enrollment , pregnant Diagnosed urinary tract infection ( UTI ) Screening Enrollment Note : Otherwise eligible participant diagnose UTI screen offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 45 day obtain informed consent screening , participant may enrol . Diagnosed pelvic inflammatory disease , sexually transmit infection ( STI ) reproductive tract infection ( RTI ) require treatment per current Centers Disease Control Prevention ( CDC ) guideline ( http : //www.cdc.gov/std/treatment/ ) Screening Enrollment Note : Otherwise eligible participant diagnose STI RTI screen offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 45 day obtain informed consent screening , participant may enrol . At Screening Enrollment , clinically apparent Grade 1 high pelvic exam finding ( observe study clinician designee ) per Division AIDS Table Grading Severity Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) , Addendum 1 , Female Genital Grading Table Use Microbicide Studies Note : Cervical friability bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment IoR/designee consider expect nonmenstrual bleeding exclusionary . At Screening , severe pelvic relaxation either vaginal wall uterine cervix descend beyond vaginal introitus valsalva maneuver Has condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Anti-HIV agent</keyword>
	<keyword>HIV-1</keyword>
</DOC>